Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 38.58M | 28.49M | 4.76M | 6.03M | 38.16M | 29.39M |
Gross Profit | 37.38M | 28.28M | 4.62M | 5.75M | 37.99M | 29.21M |
EBITDA | -305.00K | -5.42M | -39.36M | -16.84M | 16.52M | 13.81M |
Net Income | -11.95M | -13.82M | -40.83M | -17.10M | 15.80M | 13.30M |
Balance Sheet | ||||||
Total Assets | 223.46M | 221.28M | 234.30M | 140.38M | 166.56M | 125.28M |
Cash, Cash Equivalents and Short-Term Investments | 83.94M | 105.18M | 153.45M | 58.16M | 94.10M | 84.22M |
Total Debt | 114.58M | 119.20M | 124.45M | 34.00K | 229.00K | 21.26M |
Total Liabilities | 131.00M | 139.36M | 145.58M | 16.37M | 24.69M | 38.86M |
Stockholders Equity | 92.45M | 81.92M | 88.72M | 124.01M | 141.88M | 86.42M |
Cash Flow | ||||||
Free Cash Flow | -9.33M | -13.77M | -18.18M | -36.13M | -3.82M | 8.88M |
Operating Cash Flow | -9.33M | -13.75M | -18.16M | -12.88M | 22.68M | 10.09M |
Investing Cash Flow | -33.60M | -28.26M | -711.00K | -20.22M | -26.50M | -209.00K |
Financing Cash Flow | -11.96M | -11.13M | 120.59M | -4.45M | 12.84M | 19.79M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $425.97M | ― | -12.42% | ― | 194.98% | 38.01% | |
53 Neutral | $209.82M | ― | -22.84% | ― | 6.05% | 2.24% | |
52 Neutral | $615.80M | ― | -68.21% | ― | -97.15% | 54.85% | |
51 Neutral | $7.95B | -0.40 | -41.62% | 2.21% | 22.29% | -1.85% | |
48 Neutral | $272.40M | ― | -13.01% | ― | 11.78% | -504.50% | |
44 Neutral | $662.84M | ― | -437.92% | ― | -78.63% | 1.88% | |
42 Neutral | $226.47M | ― | -257.38% | ― | ― | 63.92% |
On August 11, 2025, XOMA Royalty Corporation completed its merger with Turnstone Biologics Corp., following a successful tender offer for Turnstone’s outstanding shares. This merger, executed without requiring a stockholder vote, positions XOMA as the sole owner of Turnstone, potentially enhancing its market position and operational capabilities in the biotechnology sector.